Eupraxia Pharmaceuticals Inc

詳細情報 Eupraxia Pharmaceuticals Inc 企業名

Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.

企業情報

企業コードEPRX

会社名Eupraxia Pharmaceuticals Inc

上場日Mar 09, 2021

最高経営責任者「CEO」Dr. James A. Helliwell, M.D.

従業員数33

証券種類Ordinary Share

決算期末Mar 09

本社所在地201-2067 Cadboro Bay Rd.

都市VICTORIA

証券取引所The Toronto Stock Exchange

国Canada

郵便番号V8R 5G4

電話番号12505903968

ウェブサイトhttps://eupraxiapharma.com/home/default.aspx

企業コードEPRX

上場日Mar 09, 2021

最高経営責任者「CEO」Dr. James A. Helliwell, M.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Michael Wilmink, M.D.

Independent Director

224.87K

--

Dr. Amanda Malone

Chief Operating and Scientific Officer

46.34K

+18.22%

Richard M. Glickman ,

Independent Director

13.93K

--

Mr. Adam Peeler

Investor relations

--

Mr. Joseph Freedman

Independent Director

--

Mr. John S. Montalbano

Independent Director

--

Mr. Paul A. Brennan

Chief Business Officer

--

Mr. Alexander Rothwell

Chief Financial Officer

--

Dr. Simon Pimstone, M.D., Ph.D.

Independent Chairman of the Board

--

Mr. Paul Geyer

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Michael Wilmink, M.D.

Independent Director

224.87K

--

Dr. Amanda Malone

Chief Operating and Scientific Officer

46.34K

+18.22%

Richard M. Glickman ,

Independent Director

13.93K

--

Mr. Adam Peeler

Investor relations

--

Mr. Joseph Freedman

Independent Director

--

Mr. John S. Montalbano

Independent Director

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Mon, Jun 2

株主統計

種類

株主統計

比率

Disbrow (Robert)

8.04%

Scotia Capital Inc.

4.32%

Freedman (Joseph S)

4.20%

Montalbano (John S.)

3.37%

Helliwell (James Allen)

1.87%

Other

78.19%

株主統計

比率

Disbrow (Robert)

8.04%

Scotia Capital Inc.

4.32%

Freedman (Joseph S)

4.20%

Montalbano (John S.)

3.37%

Helliwell (James Allen)

1.87%

Other

78.19%

種類

株主統計

比率

Individual Investor

19.13%

Research Firm

4.43%

Investment Advisor

1.64%

Hedge Fund

0.03%

Other

74.78%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

27

9.07M

25.23%

+3.18M

2025Q1

33

13.45M

37.66%

+9.00M

2024Q4

29

12.81M

35.95%

+8.38M

2024Q3

26

11.48M

34.74%

+5.59M

2024Q2

21

8.52M

26.42%

+4.35M

2024Q1

12

3.99M

17.06%

-637.88K

2023Q4

16

7.00M

38.32%

+2.38M

2023Q3

16

7.01M

38.38%

+2.38M

2023Q2

15

6.89M

39.05%

+2.27M

2023Q1

16

6.89M

40.01%

+2.40M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Disbrow (Robert)

2.89M

8.04%

+2.89M

--

Sep 30, 2024

Scotia Capital Inc.

1.55M

4.32%

+160.96K

+11.57%

Mar 31, 2025

Freedman (Joseph S)

1.51M

4.2%

+10.00K

+0.67%

Jun 18, 2025

Montalbano (John S.)

1.21M

3.37%

--

Apr 25, 2025

Helliwell (James Allen)

674.01K

1.87%

--

Apr 25, 2025

Geyer (Paul L)

340.35K

0.95%

--

Apr 25, 2025

Wilmink (Michael)

224.87K

0.63%

--

Apr 25, 2025

RBC Dominion Securities, Inc.

206.63K

0.57%

+59.68K

+40.62%

Mar 31, 2025

RBC Phillips, Hager & North Investment Counsel Inc.

136.20K

0.38%

--

Mar 31, 2025

TD Waterhouse Canada, Inc.

104.99K

0.29%

+104.99K

--

Mar 31, 2025

詳細を見る

5.270USD

Eupraxia Pharmaceuticals Inc

5.270

概要

企業名

金融